Skip to main content
Log in

Novel approaches for quantifying beta synchrony in Parkinson’s disease

  • Review
  • Published:
Experimental Brain Research Aims and scope Submit manuscript

Abstract

Despite the clinical and financial burden of Parkinson’s disease (PD), there is no standardized, reliable biomarker to diagnose and track PD progression. Instead, PD is primarily assessed using subjective clinical rating scales and patient self-report. Such approaches can be imprecise, hindering diagnosis and disease monitoring. An objective biomarker would be beneficial for clinical care, refining diagnosis, and treatment. Due to widespread electrophysiological abnormalities both within and between brain structures in PD, development of electrophysiologic biomarkers may be feasible. Basal ganglia recordings acquired with neurosurgical approaches have revealed elevated power in the beta frequency range (13–30 Hz) in PD, suggesting that beta power could be a putative PD biomarker. However, there are limitations to the use of beta power as a biomarker. Recent advances in analytic approaches have led to novel methods to quantify oscillatory synchrony in the beta frequency range. Here we describe some of these novel approaches in the context of PD and explore how they may serve as electrophysiological biomarkers. These novel signatures include (1) interactions between beta phase and broadband (> 50 Hz, “gamma”) amplitude (i.e., phase amplitude coupling, PAC), (2) asymmetries in waveform shape, (3) beta coherence, and (4) beta “bursts.” Development of a robust, reliable, and readily accessible electrophysiologic biomarker would represent a major step towards more precise and personalized care in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Not applicable.

Code availability

Not applicable.

References

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

Authors

Contributions

Idea for the article: NCS; Literature search: AK, SM, and NCS; Drafted and revised: AK, SM, and NCS.

Corresponding author

Correspondence to Nicole C. Swann.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Consent for publication was obtained.

Additional information

Communicated by Winston D Byblow.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karekal, A., Miocinovic, S. & Swann, N.C. Novel approaches for quantifying beta synchrony in Parkinson’s disease. Exp Brain Res 240, 991–1004 (2022). https://doi.org/10.1007/s00221-022-06308-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00221-022-06308-8

Keywords

Navigation